SCHEMBL8206827

SCHEMBL8206827

CO[SiH2]CCCNCCNCCN

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.48
CA6 P23280 5/20 0.48
CA7 P43166 5/20 0.48
CA9 Q16790 5/20 0.48
CA14 Q9ULX7 5/20 0.48
CA5B Q9Y2D0 5/20 0.48
CA2 P00918 4/20 0.48
CA4 P22748 4/20 0.48
CA5A P35218 4/20 0.48
LMNA P02545 3/20 0.48
CA3 P07451 3/20 0.48
TDP1 Q9NUW8 3/20 0.48
ALOX15 P16050 3/20 0.48
CA1 P00915 2/20 0.48
ALDH1A1 P00352 1/20 0.48
TP53 P04637 1/20 0.48
KDM4E B2RXH2 1/20 0.46
CASP2 P42575 2/20 0.44
MEN1 O00255 2/20 0.43
RECQL P46063 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19669 0.98 CA12 (0.48) CA12CA6CA7CA9CA14
SCHEMBL27591294 0.96 CA12 (0.46) CA12CA6CA7CA9CA14
SCHEMBL8984823 0.89 CYP2C19 (0.35) CA12CA6CA7CA9CA14
SCHEMBL28735575 0.81 TSHR (0.39) CA12CA6CA7CA9CA14
SCHEMBL23327735 0.81 ALDH1A1 (0.37) LMNATDP1ALOX15ALDH1A1TP53
SCHEMBL28647993 0.80 TSHR (0.40) ALDH1A1MEN1KMT2ACYP1A2CYP2C19
SCHEMBL687065 0.80 TSHR (0.46) CA12CA7CA14CA2CA1
SCHEMBL31297376 0.79 CA12 (0.52) CA12CA6CA7CA9CA14
SCHEMBL28097925 0.79 CA12 (0.44) CA12CA6CA7CA9CA14
SCHEMBL29048093 0.79 CA12 (0.39) CA12CA6CA7CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250352486-A1 NANOPARTICLES FOR USE IN THE TREATMENT OF INFECTIONS CAUSED BY BIOFILMS UNIVERSITAT POLITÈCNICA DE VALÈNCIA (ES) 2025-11-20 US disclosed
EP-4529916-A1 NANOPARTICLES FOR USE IN THE TREATMENT OF INFECTIONS CAUSED BY BIOFILMS Universitat Politècnica de València (ES) 2025-04-02 EP disclosed
EP-3286253-A1 PROCESS FOR MODIFYING POLYMERS Akzo Nobel Chemicals International B.V. (NL) 2018-02-28 EP disclosed
US-20170165375-A1 ANTIBIOTIC PROTOCELLS AND RELATED PHARMACEUTICAL FORMULATIONS AND METHODS OF TREATMENT SANDIA CORPORATION 2017-06-15 US disclosed
WO-2016170018-A1 PROCESS FOR MODIFYING POLYMERS AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) 2016-10-27 WO disclosed
WO-2015175850-A1 RESIN-COATED SUBSTRATE COMPOSITIONS AND METHODS OF MAKING THE SAME U.S. SILICA COMPANY (US) 2015-11-19 WO disclosed
EP-1025145-A1 MEANS AND METHODS FOR ENHANCING INTERFACIAL ADHESION BETWEEN A METAL SURFACE AND A NON-METALLIC MEDIUM AND PRODUCTS OBTAINED THEREBY N.V. BEKAERT S.A. (BE) 2000-08-09 EP disclosed
WO-1999020682-A1 MEANS AND METHODS FOR ENHANCING INTERFACIAL ADHESION BETWEEN A METAL SURFACE AND A NON-METALLIC MEDIUM AND PRODUCTS OBTAINED THEREBY N.V. BEKAERT S.A. (BE) 1999-04-29 WO disclosed
US-5698725-A IMINE-CONTAINING ORGANOSILICON COMPOUND DOW CORNING TORAY SILICONE CO., LTD. (JP) 1997-12-16 US disclosed
EP-0768313-A2 A surface treating agent for glass fiber substrates Dow Corning Toray Silicone Company Limited (JP) 1997-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170165375-A1 ANTIBIOTIC PROTOCELLS AND RELATED PHARMACEUTICAL FORMULATIONS AND METHODS OF TREATMENT PHOSPHO1, LIPA, BCR CA12 1591/4885CA6 1988/4885CA7 3167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.